

CDX2 Regulates *Multidrug Resistance 1* Gene Expression in Malignant Intestinal Epithelium

Yuji Takakura¹, Takao Hinoi², Naohide Oue³, Tatsunari Sasada¹, Yasuo Kawaguchi¹, Masazumi Okajima², Aytekin Akyol⁴, Eric R. Fearon⁴, Wataru Yasui³, and Hideki Ohdan¹

Abstract

The caudal-related homeobox transcription factor CDX2 has a key role in intestinal development and differentiation. *CDX2* heterozygous mutant mice develop colonic polyps, and loss of CDX2 expression is seen in a subset of colon carcinomas in humans. Ectopic CDX2 expression in the stomach of transgenic mice promotes intestinal metaplasia, and CDX2 expression is frequently detected in intestinal metaplasia in the stomach and esophagus. We sought to define CDX2-regulated genes to enhance knowledge of CDX2 function. HT-29 colorectal cancer cells have minimal endogenous CDX2 expression, and HT-29 cells with ectopic CDX2 expression were generated. Microarray-based gene expression studies revealed that the *Multidrug Resistance 1 (MDR1/P-glycoprotein/ABCB1)* gene was activated by CDX2. Evidence that the *MDR1* gene was a direct transcriptional target of CDX2 was obtained, including analyses with *MDR1* reporter gene constructs and chromatin immunoprecipitation assays. RNA interference-mediated inhibition of CDX2 decreased endogenous *MDR1* expression. In various colorectal cancer cell lines and human tissues, endogenous *MDR1* expression was well correlated to CDX2 expression. Overexpression of CDX2 in HT-29 cells revealed increased resistance to the known substrate of *MDR1*, vincristine and paclitaxel, which was reversed by an *MDR1* inhibitor, verapamil. These data indicate that CDX2 directly regulates *MDR1* gene expression through binding to elements in the promoter region. Thus, CDX2 is probably important for basal expression of *MDR1*, regulating drug excretion and absorption in the lower gastrointestinal tract, as well as for multidrug resistance to chemotherapy reagent in CDX2-positive gastrointestinal cancers. *Cancer Res*; 70(17): 6767–78. ©2010 AACR.

Introduction

There has long been great interest in defining critical regulatory factors that direct cell fate determination and differentiation in normal and cancer tissues. In mammals, the CDX1 and CDX2 homeobox transcription factors apparently have critical functions in intestinal development, differentiation, and maintenance of the intestinal phenotype (1, 2). CDX1 and CDX2 proteins show significant homology, particularly in their homeobox DNA-binding domains, to the protein product of the *Drosophila caudal gene*, a key regulator of

anterior-posterior regional identity (1, 3, 4). Mouse *Cdx1* and *Cdx2* genes are quite broadly expressed during early embryonic development. Recent studies indicated that *Cdx2* is one of the earliest transcription factors essential for formation and maintenance of the trophectoderm lineage in mouse embryos (5, 6). However, in later stages of development and in normal adult tissues, expression of the genes is apparently restricted to epithelium of the small intestine and colon (1). In support of the view that CDX proteins play key roles in regulating proliferation and intestinal cell fate, mice with constitutional inactivating mutations in one *Cdx2* allele (*Cdx2±*) developed multiple polyps in the proximal colon (7–10). The epithelial cells in these polyps often lose intestinal differentiation features, displaying areas of stratified squamous epithelium similar to that in forestomach and distal esophagus as well as areas resembling normal gastric mucosa (7, 11). Ectopic expression of *Cdx2* in the gastric mucosa of transgenic mice was reported to induce intestinal metaplasia (12, 13). In humans, loss of the *CDX1* and/or *CDX2* gene and protein expression was observed in a subset of primary colorectal cancers (CRC) and cancer cell lines (14), usually in poorly differentiated CRCs (15). Aberrant (ectopic) expression of CDX2 is detected frequently in intestinal metaplasia of the stomach (16, 17).

Our prior efforts to identify CDX2-regulated genes indicated that liver intestine-cadherin (LI-cadherin) and hephaestin

Authors' Affiliations: Departments of ¹Surgery, ²Endoscopic Surgery and Surgical Science, and ³Molecular Pathology, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan; and ⁴Division of Molecular Medicine and Genetics, Departments of Internal Medicine, Human Genetics, and Pathology, University of Michigan Medical School, Ann Arbor, Michigan

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Present address for A. Akyol: Hacettepe University School of Medicine, Department of Pathology, Ankara, Turkey.

Corresponding Author: Takao Hinoi, Department of Endoscopic Surgery and Surgical Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. Phone: 81-82-257-5222; Fax: 81-82-257-5224; E-mail: thinoi@hiroshima-u.ac.jp.

doi: 10.1158/0008-5472.CAN-09-4701

©2010 American Association for Cancer Research.

(HEPH) were likely key molecules regulated by CDX2 in normal and malignant gastrointestinal epithelium (16, 18).

Here, we report on further studies to implicate CDX2 in regulating the expression of intestinal-specific genes by using high-density oligonucleotide microarrays as a starting point to identify potential CDX2-regulated genes in HT-29, a CRC cell line with significantly decreased endogenous CDX2 expression. In HT-29 cell line engineered to express CDX2 ectopically, the gene for *Multidrug Resistance 1 (MDR1)* was strongly activated.

Of some potential interest, *MDR1* was originally identified as an overexpressed and amplified gene in multiple drug-resistant cells, and its product, P-glycoprotein, seems to play a critical role in drug resistance (19). We provide data here implicating CDX2 as an important factor in regulation of *MDR1* expression in gastrointestinal tissues.

Materials and Methods

Plasmids

A full-length, wild-type *CDX2* and *CDX1* allele were amplified by PCR using hexamer-primed complementary DNA (cDNA) from normal human colon tissue as a template. Sequence coding Flag epitope was added to the 5' ends of *CDX1* allele. The *CDX2* and Flag-*CDX1* allele were inserted into the multiple cloning site of the retroviral expression vector pPGS-CMV-CITE-neo (pPGS-neo, provided by G. Nabal, NIH, Bethesda, MD) to generate pPGS-CDX2. The full-length, wild-type *CDX2* allele was also subcloned into the retroviral vector pBabe-Puro ER (provided by A. Friedman, Johns Hopkins Oncology Center, Baltimore, MD; ref. 20) to generate pCDX2-ER. The pCDX2-ER vector encodes a chimeric protein in which full-length CDX2 sequences are fused upstream of a mutated estrogen receptor (ER) ligand-binding domain. The mutated ER ligand-binding domain no longer binds estrogen, but retains the ability to bind tamoxifen. Fragments from human *MDR1* and *glyceraldehyde-3-phosphate dehydrogenase (GAPDH)* genes were generated by PCR using hexamer-primed cDNA from Caco2 cells as a template (16). A 309-bp fragment of *MDR1* cDNA was amplified using forward primer 5'-CAGTGAACCTGACTCTATGAGATG-3' and reverse primer 5'-AGCAAGGCAGTCAGTTACAGTCC-3'. The *MDR1* and *GAPDH* cDNA fragments were subcloned into the pGEM-T Easy Vector (Promega). Genomic DNA sequences from the promoter regions of the human *MDR1* gene were cloned by PCR, using genomic DNA purified from DLD-1 cells as a template, with the reverse primer 5'-GGCTCGAGGAAACAGGTTGAATTTCCAGG-3' and the following forward primers: 5'-GCGGGTACCAGGCATTTAGCCTACTAGTG-3' (from -4,003), 5'-ATGGTACCACATGTGAAAGG-GTGGAGAGTG-3' (from -3,414), 5'-CCGGTACC-ATGTCAGTGGAGCAAAGAAATG-3' (from -1,711), and 5'-CCGGTACCGTGAACAATGCTGTACTTGC-3' (from -1,422). The PCR products were digested with Kpn1 and Xho1 (sites underlined in the primers) and subcloned into pGL4.10 [*luc2*] vector (Promega). PCR-based approaches were used to introduce mutations into the presumptive CDX2-binding sites in the pGL4.10-MDR1 (-4,203/+50)

reporter gene construct. Sequence of presumptive CDX2 binding site A (ATTATG) and B (TTTATG) were changed to ACCTGCG and TCCTGCG in the primer using the primers: 5'-GCGGTACCAGGCATTTAGCCTACTAGTGTAATTTCC-GCAGGTC-3' and 5'-GAGCGGGCTTCTCAGATGATATGTGCTTTTACTCTGTGC-3' (for binding site A), and 5'-GCGGTACCAGGCATTTAGCCTACTAGTG-3', 5'-GCATGTCTTCATACGCAGGAATCATTACATGTG-3', 5'-GCGTATGAAGGACATGTGATGATAGGGG-3', and 5'-GGGCTTCTCAGATGATATGTGCTTTTCACTC-3' (for binding site B). All fragments generated by PCR were verified by automated sequencing of the respective plasmid constructs. Plasmid pGL4.74 [*hRluc*/TK] vector (Promega) was used as control for transfection efficiency in reporter assays.

Cell culture and retrovirus infections

The amphotropic Phoenix packaging cell line was provided by G. Nolan (Stanford University, Stanford, CA). All other cell lines were obtained from the American Type Culture Collection in 1998 to 2000. Frozen stock was made immediately and stored in liquid nitrogen until the initiation of this study. After thawing frozen stock, the cells were kept at low passage throughout the study. The cell morphology was monitored by microscopy and confirmed that their morphologic images were maintained in comparison with the original morphologic images. Details of cell culture conditions were previously described (16). The Phoenix packaging cells were transfected with retroviral expression constructs (pPGS-CDX2, pPGS-neo, pPGS-Flag-CDX1, and pCDX2-ER); the supernatant containing nonreplicating amphotropic virus was harvested as previously described (16). HT-29 cells were infected with virus, selected, and maintained in media containing G418 (Invitrogen) or Puromycin (Sigma). In HT-29 cells expressing the CDX2-ER fusion protein (HT-29/CDX2-ER), CDX2 function was activated by addition of 4-hydroxytamoxifen (4-OHT; Sigma) to the growth medium at a final concentration of 500 nmol/L. To assess *MDR1* as a direct CDX2-regulated target gene, HT-29/CDX2-ER cells were treated with the protein synthesis inhibitor cycloheximide (Sigma) at a concentration of 1 μ g/mL.

Complementary RNA synthesis and gene expression profiling

Total RNA was prepared by Trizol (Invitrogen) extraction and purification with the RNeasy Cleanup kit (Qiagen). Gene expression analyses were performed with GeneChip Human Genome U95Av2 and U133A (Affymetrix, Inc.) following supplier instructions. Affymetrix arrays were scanned using the GeneArray scanner (Affymetrix); image analysis was performed with the GeneChip 4.0 software (Affymetrix).

Northern blot analysis

For each sample, 10 μ g of total RNA were fractionated by electrophoresis and transferred to a Zeta-Probe GT membrane (Bio-Rad Laboratories). Hybridization was performed using ³²P-radiolabeled cloned cDNA fragments of *MDR1*, as previously described (16). The membrane was stripped and reprobed with *GAPDH* cDNA to confirm equivalent loading and RNA transfer.

Western blot assays

Western blot analysis was performed essentially as previously described (16). Anti-CDX2 mouse monoclonal antibodies (clone 7C7/D4, BioGenex Laboratories, Inc.), antihuman MDR1 monoclonal antibody (clone C219, Calbiochem), and anti-Flag M2 monoclonal antibody (Sigma) were used at 1:10,000, 1:50, and 1:500 dilutions, respectively. The membrane was stripped and reprobed with an anti- β -actin monoclonal antibody (clone AC-15; Sigma) to verify loading and transfer.

RNA interference

Two small interfering RNA (siRNA) duplexes targeting CDX2 (5'-AACCAGGACGAAAGACAAAUA-3', CDX2 siRNA-1; and 5'-AAGCCUCAGUGUCUGGCUCUG-3', CDX2 siRNA-2) and a nonsilencing siRNA duplex (5'-AAUUCUCCGAACGUGUCACGU-3') were synthesized by Qiagen-Xeragon. Cells were cultured in antibiotic-free medium for 24 hours before transfection. They were then transfected with siRNA (340 pmol) using DharmaFECT1 (Dharmacon). Silencing was examined 72 hours after transfection. Each sample was reverse transcribed using the ReverTra Ace qPCR RT kit (Toyobo) following supplier protocols. Quantitative PCR (qPCR) analysis was performed on an ABI 7500HT with Power SYBR Green PCR Master Mix (Applied Biosystems). *MDR1* primers were as follows: forward, 5'-ATAATGCGACAGGAGATAGG-3'; and reverse, 5'-CCAAAATCACAAGGGTTAGC-3'. *GAPDH* primers were as follows: forward, 5'-TTGAGGTCAATGAAGGGG-3'; and reverse, 5'-GAAGGTGAAGGTCGGAGTC-3'. All experiments were conducted three times. Human *GAPDH* was measured as the internal control.

Reporter gene assays

At 48 hours before transfection, cells were seeded in 35-mm dishes. HT29/PGS-CDX2 and HT29/PGS-neo cells were transfected at 50% to 80% confluency with 4 μ L of Lipofectamine 2000 (Invitrogen), 0.5 μ g of pGL4.10 reporter gene construct, and 0.05 μ g of control plasmid pGL4.74. At 40 hours after transfection, cells were collected and resuspended in passive lysis buffer (Promega). Luciferase activity was determined with a dual luciferase assay system (GloMax96 Microplate Luminometer, Promega).

Chromatin immunoprecipitation assay

The chromatin immunoprecipitation (ChIP) assays were performed using the ChIP-IT Express kit (Active Motif) following supplier instructions. Chromatin extracts containing DNA fragments (average size, 500 bp) were immunoprecipitated using 2 μ g monoclonal anti-*CDX2* antibody (7C7/D4) or 2 μ g nonimmunized mouse IgG whole molecule (negative control, Active Motif). Fragments (200 bp) of the *MDR1* promoter regions were PCR amplified using the primers 5'-CCTGGGAGACAGAGTAATAC-3' (forward) and 5'-CAAAGTGGACAGAGACTTATAC-3' (reverse; -4,100/-3,882, including binding site A), and 5'-ATCCCCTATCAAGTACAGTC-3' (forward) and 5'-CTCAGTCCAAAGAGCAGAC-3' (reverse; -3,482/-3,296, including binding site B). As a negative control, a .4-kb DNA fragment from exon 3 of the *CDX1* gene was amplified by PCR using previously described

primers (18). Each immunoprecipitated DNA sample was quantified using the average of duplicate qPCRs. All ChIP-qPCR signals were normalized to the input (labeled as IP/input). Each primer gave a single product of the right size, as confirmed by agarose gel electrophoresis.

Immunohistochemical staining

Formalin-fixed, paraffin-embedded tissues were stained using the avidin-biotin complex method as previously described (16). Mouse monoclonal anti-CDX2 antibody 7C7/D4 and mouse monoclonal anti-MDR1 antibody (clone C494; Zymed Laboratories) were used at 1:1,000 and 1:10 dilution, respectively.

Cytotoxicity assay

Paclitaxel and verapamil were purchased from Sigma, and 5-fluorouracil was provided by Kyowa Hakko Kogyo Co. Ltd. Doxorubicin and vincristine were provided by Nippon Kayaku. Camptothecin and cisplatin were purchased from LKT Laboratories. MTT cytotoxicity assay was used to examine cell survival after exposure to chemotherapeutic agents. Cells were seeded at 5,000 cells/100 μ L per well in 96-well microtiter plates. After a 48-hour incubation period, cells were treated with a range of concentrations of each chemotherapeutic agent. To examine the effect of verapamil, a known P-glycoprotein inhibitor (21), 2 μ mol/L were administered together with each chemotherapeutic agent. A pilot experiment showed that this concentration was not cytotoxic to HT-29/PGS-CDX2 or HT-29/PGS-neo cells (data not shown). After 72 hours, 10 μ L of MTT dye (5 mg/mL) was added to each well, and plates were incubated for 4 hours at 37°C in a humidified 5% CO₂ atmosphere. Dark blue formazan crystals formed by live cells were dissolved in 100 μ L of solubilization solution (10% SDS in 0.01 mol/L HCl). Absorbance in individual wells was determined at 570 nm using an MTP-300 microplate reader (CORONA Electric Co. Ltd.). Results were expressed in terms of the concentration required to inhibit cell growth by 50% relative to nontreated cells [IC₅₀ (72 h)].

Results

CDX2 and *MDR1* expression are correlated in colon carcinoma cells

Similar to a few selected other human CRC cell lines, the HT-29 line shows very low endogenous CDX2 expression (22). To identify candidate CDX2-regulated genes, we generated polyclonal populations of HT-29 CRC cells ectopically expressing CDX2, by infecting the cells with replication-defective retroviruses carrying full-length human *CDX2* cDNA (Fig. 1A). Comparison of gene expression in the HT-29/PGS-CDX2 cells versus control populations (HT-29/PGS-neo) was performed using microarrays with focus on the *MDR1* (*ABCB1*) gene. Affymetrix data indicated that *MDR1* gene expression was upregulated by CDX2 by roughly 31.14-fold in HT-29 cells (Fig. 1A). Northern and Western blot studies confirmed robust induction of *MDR1* transcripts and protein in HT-29/PGS-CDX2 cells (Fig. 1B). To determine whether MDR1 is a selective CDX2 target, we also generated polyclonal




Figure 1. CDX2 activates *MDR1* expression in HT-29 cells. A, top, a monoclonal anti-CDX2 antibody detects the roughly 40-kDa CDX2 protein in HT-29/PGS-CDX2 cells but not in HT-29/PGS-neo cells. A, bottom, relative level of *MDR1* gene expression in HT-29/PGS-CDX2 and HT-29/PGS-neo in Affymetrix microarray studies. B, Northern and Western blot analysis detects *MDR1* transcripts and products in HT-29/PGS-CDX2 with low or absent *MDR1* expression in HT-29/PGS-neo cells. In Western blot analysis, a mouse monoclonal anti-*MDR1* antibody detects the roughly 170-kDa *MDR1* product in HT-29/PGS-CDX2 cells but not in HT-29/PGS-neo cells. C, expression of CDX2 and *MDR1* in 13 CRC cell lines. Western blot analyses of *MDR1* and CDX2 expression were performed using a mouse monoclonal antibody against human *MDR1* and a mouse monoclonal antibody against human CDX2. The membranes were stripped and reprobbed with a monoclonal antibody against β -actin to verify loading and transfer. Northern blot analysis of *MDR1* expression was performed using an *MDR1* cDNA probe. The membrane was stripped and reprobbed with a GAPDH cDNA probe to verify loading and transfer.

populations of HT-29 cells ectopically expressing CDX1 (HT-29/PGS-Flag-CDX1). In this cell line, *MDR1* expression was not induced by overexpression of CDX1 (Supplementary Fig. S1).

To assess the correlation between endogenous *CDX2* and *MDR1* expression in other CRC cell lines, Northern and Western blot analyses were performed on 12 additional lines. *MDR1* protein expression was detected in six cell lines with high levels of *MDR1* transcripts. In all of these cell lines, strong *CDX2* expression was observed (Fig. 1C, lanes 1, 2, 5, 9, 11, and 12, 5, 9, 11, and 12). However, none of the cell lines with weak or undetectable *CDX2* expression had detectable *MDR1* transcripts or protein.

The *MDR1* gene is a primary target of CDX2 activity

To better assess the relationship between *CDX2* function and *MDR1* gene expression, we studied *MDR1* expression in

an HT-29–derived line with tightly regulated *CDX2* activity. We used a polyclonal HT-29 cell line that had been transduced with a vector encoding a chimeric CDX2-ER fusion protein. In the chimeric CDX2-ER protein, full-length CDX2 sequences are present upstream of a mutated ER ligand-binding domain. The mutant ER ligand-binding domain is capable of binding to 4-OHT, but not estrogen. Expression of the CDX2-ER fusion protein in HT-29/CDX2-ER polyclonal cell line was confirmed (data not shown). Treatment of HT-29/CDX2-ER cell line with 4-OHT strongly induced *MDR1* expression within 12 hours, with further increased expression up to day 2 of 4-OHT treatment (Fig. 2A). Consistent with the notion that *MDR1* is a direct or primary target gene regulated by *CDX2*, blockade of new protein synthesis by cycloheximide treatment did not inhibit induction of *MDR1*

transcripts at the 12-hour time point (Fig. 2B). However, as expected, cycloheximide treatment blocked induction of *MDR1* protein expression in 4-OHT-treated HT-29/CDX2-ER cells (Fig. 2B).


Inhibition of CDX2 by RNA interference results in the downregulation of *MDR1* in colon cancer cells

To determine whether CDX2 is necessary for *MDR1* expression in mammalian cells, we analyzed the effect of inhibiting CDX2 expression by RNA interference in the level of *MDR1* expression. DLD-1, a CRC cell line with high endogenous CDX2 and *MDR1* expression, was used. CDX2-specific siRNAs significantly suppressed CDX2 protein expression 3 days after transfection, and expression of *MDR1* transcript was downregulated roughly 50% by CDX2 siRNAs in DLD1 compared with its levels in parental and control siRNA-treated cells (Fig. 2C). These data indicate that CDX2 is involved in maintaining *MDR1* gene expression in gastrointestinal cell lines.

The 5'-flanking region of the *MDR1* gene contains a CDX2-responsive element

To identify potential CDX2-binding sites in the *MDR1* promoter region, genomic sequences immediately 5' to the apparent transcription start site were searched, using a consensus-binding element for the Cdx A chicken caudal-related protein (5'-A, A/T, T, A/T, A, T, A/G-3'; ref. 23) and a previously described search algorithm (24). Four candidate CDX2-binding sites were found in the -4.0-kb region upstream of the presumptive transcription initiation sites: site A (5'-ATTTATG-3', from -3,974 to -3,980), site B (5'-TTTTATG-3', from -3,421 to -3,427), site C (5'-TTTTATG-3', from -1,489 to -1,495), and site D (5'-ATTTATG-3', from -1,463 to -1,469; Fig. 3A). To assess the role of these presumptive CDX2-binding sites in regulating *MDR1* transcription, several reporter gene constructs were generated (Fig. 3A). Reporter gene constructs containing 4.0 kb of a 5'-flanking sequence (-4,003/+50) from the *MDR1* gene showed strong activity in the HT29/PGS-CDX2 cell lines (Fig. 3B).

Figure 2. The *MDR1* gene is a primary target of CDX2 action. A, time course of *MDR1* gene induction in response to activation of a CDX2-ER fusion protein by 4-OHT. B, induction of *MDR1* transcript in response to activation of a CDX2-ER fusion protein by 4-OHT is not inhibited by the protein synthesis inhibitor cycloheximide, but protein synthesis is blocked. C, inhibition of CDX2 expression by siRNA targeting leads to decreased *MDR1* expression in CRC cell line DLD1. Assays were performed in triplicate; columns, mean; bars, SD.






Figure 3. Localization of regulatory elements and CDX2 binding sites in the 5'-flanking region of the *MDR1* gene. A, schematic representation of the 5'-flanking region of the *MDR1* gene and *MDR1* reporter gene constructs. The location and sequence of four consensus CDX2-binding sites in the 5'-flanking region of *MDR1* are indicated. The direction of the arrows indicates the strand on which the candidate CDX2-binding element was found (i.e., sense or antisense). The *MDR1* genomic DNA sequences present in the reporter gene vectors are indicated. Localized mutations in the candidate CDX2-binding sites (i.e., site A and B) were introduced into the -4,003/+50 construct as noted (bottom), and the series of constructs generated is shown. B, key sequences for *MDR1* transcription in CDX2-expressing cell lines reside between bp -4,003 and -3,414. Columns, mean values of the luciferase activity ratio in HT29/PGS-CDX2 cells to that in HT29/PGS-neo cells; bars, SD. C, CDX2 candidate binding sites A and B play critical roles in *MDR1* transcription. All assays were performed in triplicate; columns, mean of luciferase activity ratio; bars, SD.

All the *MDR1* reporter gene constructs with deletions downstream of the 4.0-kb pair site showed decreased activity in HT29/PGS-CDX2 cell lines; thus, sequences between -3.4- and -4.0-kb pairs are important in activating *MDR1* transcription. Analysis of single and multiple mutations in the presumptive CDX2-binding sites in this region using HT29/PGS-CDX2 and HT29/PGS-neo showed that the presumptive CDX2-binding sites A and B play crucial roles in activating *MDR1* transcription (Fig. 3C).


CDX2 binds to elements in the 5'-flanking region of the *MDR1* gene

As previously noted, using the HT-29/CDX-ER cell line and the protein synthesis inhibitor cycloheximide, we found that the *MDR1* gene was a direct or primary target of CDX2. Additionally, *MDR1* reporter gene studies with localized mutations of CDX2-binding sites implied that CDX2 plays a major role in activating *MDR1* transcription by binding to one or more sites in the *MDR1* proximal promoter region. To confirm that CDX2 does indeed bind

directly to sequences in the *MDR1* promoter region, we undertook ChIP assays using HT-29/CDX-ER cells. Before treatment of HT-29/CDX-ER cells with 4-OHT, the CDX2-ER fusion protein was expressed but remained inactive in the cells, likely because it was complexed with heat shock proteins. As would be predicted for cells lacking appreciable levels of functional CDX2, before 4-OHT treatment, we failed to recover DNA fragments of the promoter regions of *MDR1* in ChIP experiments with anti-CDX2 antibody (Fig. 4A). In contrast, on day 2 after 4-OHT-mediated activation of the CDX2-ER fusion protein, we readily recovered DNA fragments containing the *MDR1* promoter (Fig. 4A). The specificity of recovery of the *MDR1* promoter region following ChIP

with anti-CDX2 antibody was shown by the fact that other irrelevant DNA fragments lacking CDX2-binding sites (e.g., exon 3 of the *CDX1* gene) were not recovered (Fig. 4A). Additionally, mock immunoprecipitation (mouse IgG whole molecule) yielded few *MDR1* or CDX1-specific DNA fragments (Fig. 4A). To confirm these data in endogenous CDX2, we performed the same ChIP assay in Caco2, CRC cell lines, which has strong endogenous CDX2 expression. We also recovered DNA fragments containing the *MDR1* promoter region following ChIP with anti-CDX2 antibody (Fig. 4B). All these findings strongly suggest that CDX2 activates *MDR1* transcription by directly binding to sequences in the 5'-flanking region of the gene.

Figure 4. CDX2 binding to *MDR1* promoter region shown by ChIP. A, CDX2 function was activated in HT-29/CDX2-ER cells by treatment of the cells with 4-OHT, and the cells were harvested at the indicated time points. B, specificity of recovery of DNA fragments of *MDR1* promoter region following ChIP with anti-CDX2 antibody was confirmed in Caco2, which has endogenous strong CDX2 expression. Assays were performed in triplicate, and mean and SD values are shown.






Figure 5. CDX2 and MDR1 expressions are well correlated in human colon epithelium and stomach cancer tissues. Immunohistochemistry was performed on formalin-fixed and paraffin-embedded tissues with anti-CDX2 monoclonal antibody (A and B, left) and with anti-MDR1 monoclonal antibody, C494 (A and B, right) in (A) human colon epithelium and (B) stomach cancer tissue.

CDX2 and MDR1 expression are tightly coupled in neoplastic tissues in the gastrointestinal tract

As previously noted, prior studies of CDX2 expression in normal adult tissues have shown strong CDX2 expression restricted to epithelial cells of the small intestine and colon, whereas *MDR1* is expressed in a broad range of normal tissues including epithelia of the liver; kidney; small and large intestine; and capillary endothelial cells in brain, ovary, and testis (25).

We examined the correlation between CDX2 and MDR1 expression in human healthy colon epithelium and CRC tissue microarray by immunohistochemical staining. Patterns of CDX2 and MDR1 expression are well correlated in normal colon epithelium (Fig. 5A). In CRC tissue microarray, we analyzed 302 CRC tissues. For statistical comparisons, moderate and high *MDR1* protein (P-glyco-

protein) expression was evaluated against low *MDR1* expression. In tissue microarray, 214 showed positive CDX2 expression (70.9%), whereas 201 showed positive *MDR1* expression (66.6%). CDX2 and *MDR1* expressions showed a strong positive correlation (Supplementary Table S1, $P < 0.001$). We then evaluated the correlation between CDX2 and *MDR1* expression in stomach cancers because normal stomach epithelium shows low expression of both CDX2 and *MDR1* (16, 26). CDX2 was stained intensely in nuclei of stomach cancer cells, whereas *MDR1* was stained in the inner surface of neoplastic glands (Fig. 5B). Of 54 stomach cancers, 22 showed positive CDX2 expression (40.7%), whereas 25 showed positive *MDR1* expression (46.3%). CDX2 and *MDR1* expressions showed a strong positive correlation ($P < 0.001$; Supplementary Table S2).

HT-29 cells ectopically expressing CDX2 have MDR1-dependent drug resistance

To determine whether MDR1 induced by CDX2 functions as a drug reflux pump, we analyzed the effects of chemotherapeutic drugs on HT-29/PGS-CDX2 and HT-29/PGS-neo cells (Fig. 6A). The MDR1 nonsubstrates, that is, cisplatin, camptothecin, 5-fluorouracil, and doxorubicin, showed similar activity in HT-29/PGS-CDX2 and HT-29/PGS-neo cells, whereas the known MDR1 substrates (25), vincristine and paclitaxel, showed lesser activity [7.7- and 3.0-fold increase in IC_{50} (72 h), respectively] in HT-29/PGS-CDX2 cells (Fig. 6A).

To examine MDR1-dependent drug resistance, we conducted the same assay in the presence of the MDR1 inhibitor verapamil. Cotreatment with 2 μ mol/L verapamil increased the activities of vincristine and paclitaxel in HT-29/PGS-CDX2 cells (Fig. 6B and C). Verapamil reduced the differences in the drug-induced cytotoxicity between HT-29/PGS-CDX2 and HT-29/PGS-neo cells (Fig. 6B and C). This suggests that increased resistance to vincristine and paclitaxel in HT-29/PGS-CDX2 cells is caused by overexpression of the *MDR1* gene.

Discussion

There is now a sizable body of data supporting the idea that the intestine-specific homeobox transcription factor CDX2 has a crucial role in directing intestinal epithelial development and differentiation (1, 2). However, the precise molecular mechanisms underlying tissue-specific expression of CDX2 and its downstream target genes remain undefined. To date, only a limited number of CDX2-regulated target genes have been suggested, including sucrase-isomaltase (27), glucagon (28), carbonic anhydrase 1 (29), calbindin-D9K (30), vitamin D receptor (31), lactase (32), guanylyl cyclase C (33), clusterin (34), gut-enriched Krüppel-like factor (35), heparin-binding epidermal growth factor-like growth factor (36), *MUC2* (37), LI-cadherin (16), *HEPH* (18), *Cdx2* itself through autoregulatory loop (38), insulin receptor substrate 2 (39), and solute carrier family 5, member 8 (SLC5A8; ref. 40).

In this study, we identified *MDR1* as a candidate gene directly regulated by CDX2. Evidence that CDX2 might regulate *MDR1* was initially obtained using high-density oligonucleotide microarrays to identify genes activated following overexpression of CDX2 in a CRC cell line showing very low endogenous CDX2 expression. Additionally, data indicating that endogenous *MDR1* expression was dependent on CDX2 were obtained, along with evidence that activation of CDX2 induced *MDR1* transcripts even in the presence of protein synthesis inhibitors. We identified four presumptive CDX2-binding sites in the 4-kb region upstream of the transcription start sites of *MDR1*. Reporter gene analysis showed that two of these elements were critical. Subsequent ChIP assays showed that CDX2 binds directly to this *MDR1* promoter region. Immunohistochemical staining analysis for 302 CRCs and 54 stomach cancers showed that CDX2 and MDR1 protein expressions were significantly correlated. Given the regulation of *MDR1* by CDX2 in neoplastic gastrointestinal

tissues, CDX2, as well as MDR1, may be a useful marker for predicting the status of drug resistance in the stomach and perhaps elsewhere.

Although our data offer reliable support for the view that CDX2 plays a role in regulating *MDR1* transcription by binding to one or more elements in the proximal promoter region, CDX2 might not be sufficient for activating *MDR1* expression. It is possible that other factors along with CDX2 may be required to activate *MDR1* transcription in certain settings, such as in HT-29 cells, because two of the eight CDX2-positive CRC cell lines we studied (namely SW48 and LS174T) expressed very low or undetectable levels of *MDR1* transcripts and protein. Previously, we obtained similar evidence that CDX2 was required but not sufficient for activating *LI-cadherin* and *HEPH* transcription (16, 18). On the other hand, our data indicated that inhibition of CDX2 expression by siRNA leads to decreased *MDR1* transcription, suggesting that CDX2 does play a key role in maintaining *MDR1* expression in certain settings, such as in CDX2- and MDR1-expressing CRC cells. It will be interesting in the future to define other factors that cooperate with CDX2 in regulating *MDR1*, *LI-cadherin*, and *HEPH* expression in gastrointestinal tissues.

In our study, we showed that expression of CDX2 induced MDR1-dependent drug resistance in a CRC cell line, which was reversed by the MDR1-specific inhibitor verapamil (21), suggesting a role of CDX2 in the regulation of *MDR1* gene expression in drug resistance. Consistent with the intestine-specific expression of CDX2 in humans and mice, recent analysis for tissue-specific murine *Mdr1a* gene expression in naïve animals revealed that the basal *Mdr1a* expression level was 100-fold higher in the intestine than in other *MDR1*-expressing tissues such as the liver, kidney, and spleen (25, 41). In epithelial cells of the lower gastrointestinal tract (jejunum, ileum, and colon), high levels of MDR1 protein are found only on the apical surfaces of superficial columnar epithelial cells, which suggests a function to prevent uptake of substrates and perhaps to facilitate excretion across the mucosa of the gastrointestinal tract (26). Given the role of CDX2 in the establishment and maintenance of intestinal epithelium, CDX2 may play a critical role in protecting the intestinal epithelium and the human body from toxic xenobiotics by stably inducing *MDR1* even under naïve conditions.

In cancer tissue, the *MDR1* gene was originally identified as an overexpressed and amplified gene in multiple drug-resistant cells (19, 25). The *MDR1* gene encodes P-glycoprotein, a member of the large ATP-binding cassette superfamily of transmembrane proteins (ATP-binding cassette, sub family B, member 1) that transports structurally different hydrophobic chemotherapeutic agents outward in an energy-dependent manner. Regulation of *MDR1* gene expression is complex because like many TATA-less promoters (42), the promoter of the *MDR1* gene contains multiple start sites. In studies of CRCs, expression of *MDR1* was correlated with pathologic grading of tumors, being most intense in well-differentiated tumors and low in poorly differentiated ones (43). Similarly, moderately differentiated gastric carcinomas expressed a higher level of MDR1 than poorly differentiated




Figure 6. HT29 cells ectopically expressing CDX2 have MDR1-dependent drug resistance. A, effect of chemotherapeutic drugs on HT29/PGS-CDX2 (○) and HT29/PGS-neo (●) cell lines. B, effect of additional verapamil on vincristine and paclitaxel in HT29/PGS-CDX2 (○) and HT29/PGS-neo (●) cell lines. C, $[\text{IC}_{50}$ (72 h)] determined by MTT assay on HT29/PGS-CDX2 and HT29/PGS-neo cells. Cotreatment with verapamil significantly recovered the sensitivity of vincristine and paclitaxel on HT-29/PGS-CDX2 cells. The cytotoxic assays were performed in triplicate; points, mean; bars, SD.

ones (44). Although studies of CRCs arising in humans have not offered definitive proof of a causal role for CDX2 inactivation in the cancer process, it is quite clear that loss of CDX2 expression is seen in a subset of primary CRCs, particularly tumors with minimal differentiation (45). Consistent with our previous observation in large cell minimally differentiated adenocarcinoma of the colon, recent multivariate analysis also indicates that loss of CDX2 expression is associated with less-differentiated carcinoma and advanced stage, although CDX2 loss is not independently associated with patient survival (15, 46). Considering the roles of CDX2 in promoting cellular differentiation and inhibiting proliferation (45), CDX2 loss could conceivably contribute to aggressive tumor behavior, although MDR1 loss induced by CDX2 suppression may have some beneficial influence on patient survival with reduced drug resistance.

In conclusion, our findings implicating CDX2 in regulation of *MDR1* offer data on specific factors and mechanisms regulating MDR1 expression in gastrointestinal cancers. However, several outstanding issues regarding the transcriptional regulation of *MDR1* by CDX2 remain to be addressed. Due to the complexity of the mechanism of drug resistance, further studies of *MDR1* and its regulation by CDX2 in various

gastrointestinal cancers should help to enhance understanding of the mechanism of aberrant (ectopic) expression of CDX2 and its downstream target *MDR1*, and in the development of a strategy to select chemotherapy regimens based on the status of CDX2 and *MDR1* expression.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Drs. Hideki Yamamoto and Yoshitaka Tomoda for their advice, Yuko Ishida and Midori Kiyokawa for their expert technical assistance, and the Analysis Center of Life Science, Hiroshima University, for the use of their facilities.

Grant Support

US NIH grants CA082223, NIH R01CA082223 (E.R. Fearon).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/30/2009; revised 05/27/2010; accepted 06/11/2010; published OnlineFirst 08/10/2010.

References

- Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. *Gastroenterology* 2000;119:961–71.
- Beck F. The role of Cdx genes in the mammalian gut. *Gut* 2004;53:1394–6.
- Moreno E, Morata G. Caudal is the Hox gene that specifies the most posterior Drosophila segment. *Nature* 1999;400:873–7.
- Macdonald PM, Struhl G. A molecular gradient in early *Drosophila* embryos and its role in specifying the body pattern. *Nature* 1986;324:537–45.
- Niwa H, Toyooka Y, Shimosato D, et al. Interaction between Oct3/4 and Cdx2 determines trophoblast differentiation. *Cell* 2005;123:917–29.
- Tolkunova E, Cavaleri F, Eckardt S, et al. The caudal-related protein cdx2 promotes trophoblast differentiation of mouse embryonic stem cells. *Stem Cells* 2006;24:139–44.
- Chawengsaksophak K, James R, Hammond VE, Kontgen F, Beck F. Homeosis and intestinal tumours in Cdx2 mutant mice. *Nature* 1997;386:84–7.
- Tamai Y, Nakajima R, Ishikawa T, Takaku K, Seldin MF, Taketo MM. Colonic hamartoma development by anomalous duplication in Cdx2 knockout mice. *Cancer Res* 1999;59:2965–70.
- Bonhomme C, Duluc I, Martin E, et al. The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development. *Gut* 2003;52:1465–71.
- Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in *Apc+/-Δ716 Cdx2+/-* compound mutant mice. *Nat Genet* 2003;35:323–30.
- Beck F, Chawengsaksophak K, Waring P, Playford RJ, Furness JB. Reprogramming of intestinal differentiation and intercalary regeneration in Cdx2 mutant mice. *Proc Natl Acad Sci U S A* 1999;96:7318–23.
- Silberg DG, Sullivan J, Kang E, et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. *Gastroenterology* 2002;122:689–96.
- Mutoh H, Hakamata Y, Sato K, et al. Conversion of gastric mucosa to intestinal metaplasia in Cdx2-expressing transgenic mice. *Biochem Biophys Res Commun* 2002;294:470–9.
- Ee HC, Eler T, Bhathal PS, Young GP, James RJ. Cdx-2 homeodomain protein expression in human and rat colorectal adenoma and carcinoma. *Am J Pathol* 1995;147:586–92.
- Hinoi T, Tani M, Lucas PC, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. *Am J Pathol* 2001;159:2239–48.
- Hinoi T, Lucas PC, Kuick R, Hanash S, Cho KR, Fearon ER. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. *Gastroenterology* 2002;123:1565–77.
- Eda A, Osawa H, Yanaka I, et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. *J Gastroenterol* 2002;37:94–100.
- Hinoi T, Gesina G, Akyol A, et al. CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. *Gastroenterology* 2005;128:946–61.
- Pastan I, Gottesman MM. Multidrug resistance. *Annu Rev Med* 1991;42:277–86.
- Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. *Nucleic Acids Res* 1995;23:1686–90.
- Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia *in vivo* and *in vitro* through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res* 1981;41:1967–72.
- Mallo GV, Soubeyran P, Lissitzky JC, et al. Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells. *J Biol Chem* 1998;273:14030–6.
- Margalit Y, Yaros S, Shapira E, Gruenbaum Y, Fainsod A. Isolation and characterization of target sequences of the chicken CdxA homeobox gene. *Nucleic Acids Res* 1993;21:4915–22.
- Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. *Nucleic Acids Res* 1998;26:362–7.
- Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu Rev Pharmacol Toxicol* 1999;39:361–98.

26. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. *Proc Natl Acad Sci U S A* 1987;84:7735–8.
27. Suh E, Chen L, Taylor J, Traber PG. A homeodomain protein related to caudal regulates intestine-specific gene transcription. *Mol Cell Biol* 1994;14:7340–51.
28. Jin T, Trinh DK, Wang F, Drucker DJ. The caudal homeobox protein *cdx-2/3* activates endogenous proglucagon gene expression in InR1–9 islet cells. *Mol Endocrinol* 1997;11:203–9.
29. Drummond FJ, Sowden J, Morrison K, Edwards YH. Colon carbonic anhydrase 1: transactivation of gene expression by the homeodomain protein *Cdx2*. *FEBS Lett* 1998;423:218–22.
30. Colnot S, Romagnolo B, Lambert M, et al. Intestinal expression of the calbindin-D9K gene in transgenic mice. Requirement for a *Cdx2*-binding site in a distal activator region. *J Biol Chem* 1998;273:31939–46.
31. Yamamoto H, Miyamoto K, Li B, et al. The caudal-related homeodomain protein *Cdx-2* regulates vitamin D receptor gene expression in the small intestine. *J Bone Miner Res* 1999;14:240–7.
32. Fang R, Santiago NA, Olds LC, Sibley E. The homeodomain protein *Cdx2* regulates lactase gene promoter activity during enterocyte differentiation. *Gastroenterology* 2000;118:115–27.
33. Park J, Schulz S, Waldman SA. Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by *Cdx2*. *Gastroenterology* 2000;119:89–96.
34. Suh E, Wang Z, Swain GP, Tenniswood M, Traber PG. Clusterin gene transcription is activated by caudal-related homeobox genes in intestinal epithelium. *Am J Physiol Gastrointest Liver Physiol* 2001;280:G149–56.
35. Dang DT, Mahatan CS, Dang LH, Agboola IA, Yang VW. Expression of the gut-enriched Kruppel-like factor (Kruppel-like factor 4) gene in the human colon cancer cell line RKO is dependent on *CDX2*. *Oncogene* 2001;20:4884–90.
36. Uesaka T, Lu H, Katoh O, Watanabe H. Heparin-binding EGF-like growth factor gene transcription regulated by *Cdx2* in the intestinal epithelium. *Am J Physiol Gastrointest Liver Physiol* 2002;283:G840–7.
37. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein *CDX2* regulates goblet-specific *MUC2* gene expression. *Biochem Biophys Res Commun* 2003;300:813–8.
38. Xu F, Li H, Jin T. Cell type-specific autoregulation of the Caudal-related homeobox gene *Cdx-2/3*. *J Biol Chem* 1999;274:34310–6.
39. Modica S, Morgano A, Salvatore L, et al. Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor *CDX2*. *Gut* 2009;58:1250–9.
40. Kakizaki F, Aoki K, Miyoshi H, Carrasco N, Aoki M, Taketo MM. *CDX* transcription factors positively regulate expression of solute carrier family 5, member 8 in the colonic epithelium. *Gastroenterology* 2010;138:627–35.
41. Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE. A new model for studying tissue-specific *mdr1a* gene expression *in vivo* by live imaging. *Proc Natl Acad Sci U S A* 2009;106:5394–9.
42. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. *Biochem Pharmacol* 2002;64:943–8.
43. Potocnik U, Ravnik-Glavac M, Golouh R, Glavac D. Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. *J Med Genet* 2002;39:340–6.
44. Mizoguchi T, Yamada K, Furukawa T, et al. Expression of the *MDR1* gene in human gastric and colorectal carcinomas. *J Natl Cancer Inst* 1990;82:1679–83.
45. Hinoi T, Loda M, Fearon ER. Silencing of *CDX2* expression in colon cancer via a dominant repression pathway. *J Biol Chem* 2003;278:44608–16.
46. Baba Y, Noshio K, Shima K, et al. Relationship of *CDX2* loss with molecular features and prognosis in colorectal cancer. *Clin Cancer Res* 2009;15:4665–73.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

CDX2 Regulates *Multidrug Resistance 1* Gene Expression in Malignant Intestinal Epithelium

Yuji Takakura, Takao Hinoi, Naohide Oue, et al.

Cancer Res 2010;70:6767-6778. Published OnlineFirst August 10, 2010.

Updated version Access the most recent version of this article at:
doi:[10.1158/0008-5472.CAN-09-4701](https://doi.org/10.1158/0008-5472.CAN-09-4701)

Supplementary Material Access the most recent supplemental material at:
<http://cancerres.aacrjournals.org/content/suppl/2010/08/09/0008-5472.CAN-09-4701.DC1>

Cited articles This article cites 46 articles, 15 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/70/17/6767.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/70/17/6767.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/70/17/6767>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.